ArticleAdvanced genetics (Hoboken, N.J.)2025
Identification of Cathepsin H and Metabolic Traits as Potential Biomarkers for Lung Cancer by Mendelian Randomization and Single-Cell Transcriptomics.
Article in Advanced genetics (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Identification of Cathepsin H and Metabolic Traits as Potential Biomarkers for Lung Cancer by Mendelian Randomization and Single-Cell Transcriptomics.Advanced genetics (Hoboken, N.J.) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is a major global malignancy with debated roles for cathepsin H (CTSH), a lysosomal protease, and underexplored regulation by metabolites. We analyzed lung cancer incidence and hyperglycemia-related mortality trends (1990-2021) using Joinpoint regression. Mendelian randomization (MR), meta-analysis, and two-step mediation examined CTSH and 233 metabolic traits. Single-cell RNA sequencing (scRNA-seq) and TCGA/HPA datasets validated CTSH expression. Lung cancer incidence decreased overall but rose in women, while fasting hyperglycemia-related mortality increased. CTSH elevated lung cancer and adenocarcinoma risks, with docosahexaenoic acid (22:6) and omega-3 fatty acids driving adenocarcinoma progression. A higher linoleic acid (18:2)/total fatty acid ratio reduced risk. scRNA-seq identified CTSH in myeloid cells, especially "mo-Mac," which promoted tumors. CTSH expression patterns were evaluated using TCGA and HPA data, revealing protein-level overexpression in tumors with some divergence from transcriptomic results. CTSH is linked to lung cancer, particularly adenocarcinoma, with modest effects mediated by metabolites like omega-3 fatty acids. Its prominent expression in macrophages suggests novel therapeutic targets. These findings, though consistent, require further validation due to modest effect sizes and dataset heterogeneity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.